Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic

SAVID-FRONTERA, CONSTANZA; VIANO, MARIA ESTEFANIA; BAEZ, NATALIA S.; REYNOLDS, DELLA; MATELLÓN, MARIANA; YOUNG, HOWARD A.; RODRIGUEZ-GALAN, MARIA CECILIA

IMMUNOTHERAPY

FUTURE MEDICINE LTD

Lugar: Londres; Año: 2021

1750-743X

IL-12 has emerged as a potent cytokine in mediating antitumor activity in preclinical modelsof cancer. However, this antitumor response has not yet been translated into the clinic because of toxicside effects. The aim of our work is to analyze the effects of IL-12 in mouse tumor models. We demonstratethat one injection of IL-12 cDNA can induce systemic IL-12 levels in serum even lower than the tolerateddose in patients. At this dose, an efficient control of tumor growth can be observed. We found a higherfrequency of both total tumor-infiltrated leukocytes and IFN-γ-producing CD8+ T cells along with a lowerfrequency of regulatory CD4+FOXP3+ and CD11b+ Gr1+ cells. Our work demonstrates that IL-12 cDNA cansafely be used to treat cancer.